Last reviewed · How we verify
IMiD treatment
At a glance
| Generic name | IMiD treatment |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
- A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (PHASE2)
- Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |